Effects of chronic therapy with non-steroidal antiinflammatory drugs on gastric permeability of sucrose: a study on 71 patients with rheumatoid arthritis.
OBJECTIVE
To evaluate the gastric permeability after both acute and chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) and to assess the clinical usefulness of sucrose test in detecting and following NSAIDs- induced gastric damage mainly in asymptomatic patients and the efficacy of a single pantoprazole dose in chronic users.


METHODS
Seventy-one consecutive patients on chronic therapy with NSAIDs were enrolled in the study and divided into groups A and B (group A receiving 40 mg pantoprazole daily, group B only receiving NSAIDs). Sucrose test was performed at baseline and after 2, 4 and 12 wk, respectively. The symptoms in the upper gastrointestinal tract were recorded.


RESULTS
The patients treated with pantoprazole had sucrose excretion under the limit during the entire follow-up period. The patients without gastroprotection had sucrose excretion above the limit after 2 wk, with an increasing trend in the following weeks (P = 0.000). A number of patients in this group revealed a significantly altered gastric permeability although they were asymptomatic during the follow-up period.


CONCLUSIONS
Sucrose test can be proposed as a valid tool for the clinical evaluation of NSAIDs- induced gastric damage in both acute and chronic therapy. This technique helps to identify patients with clinically silent gastric damages. Pantoprazole (40 mg daily) is effective and well tolerated in chronic NSAID users.
Maino
Marta
M
Department of Clinical Science, University of Parma, Via Gramsci 14, Parma 43100, Italy.
Mantovani
Nicola
N
Merli
Roberta
R
Cavestro
Giulia Martina
GM
Leandro
Gioacchino
G
Cavallaro
Lucas Giovanni
LG
Corrente
Vincenzo
V
Iori
Veronica
V
Pilotto
Alberto
A
Franzè
Angelo
A
Di Mario
Francesco
F
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000494:pharmacology; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D000897:Anti-Ulcer Agents / Q000494:pharmacology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004724:Endoscopy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole; D010539:Permeability; D013270:Stomach / Q000187:drug effects*; D013395:Sucrose / Q000494:pharmacology*; D013997:Time Factors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D013395:Sucrose; D000077402:Pantoprazole